PF-Atlas › Clinical Trials › NCT01499914
Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination
influenza vaccination · Phase 4
Registry ID
NCT01499914
Phase
Phase 4
Status
Completed
Drug / intervention
influenza vaccination
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2009-11
Enrollment
439
Locations
1
About this trial
Multicenter prospective cohort of approximately 1000 cystic fibrosis patients followed in the Ile de France during the 2009-2010 influenza season with the main objective to assess the effectiveness of antiviral vaccination (H1N1). All subjects will be included, without excluding factor. In particular populations at risk are additional infants 6 to 23 months, pregnant women and lung transplant will also be included. These people will be vaccinated with un-adjuvanted vaccine. If flu symptoms until the results of PCR to confirm or refute the diagnosis of influenza, oseltamivir is administered in accordance with official recommendations and based on the results of the pharmacokinetic study.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01499914 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.